CARDIOTROPHIN-1 AS AN INDEPENDENT FACTOR OF EARLY DEVELOPMENT OF ATHEROSCLEROTIC CHANGES IN COMORBID PATIENTS

Authors:

Abstract:

The work is devoted to the study of cardiotrophin-1 as a crucial biomarker for the early development of atherosclerotic changes in patients with comorbid conditions, such as arterial hypertension, type 2 diabetes mellitus, and obesity. Considering the high prevalence of these conditions, the early detection of factors contributing to cardiovascular complications is of paramount importance. The study included 211 patients aged 49 to 65 years, divided into four groups based on the presence of arterial hypertension, type 2 diabetes mellitus, and obesity. The results show a significant increase in the level of cardiotrophin-1in patients with comorbid pathology compared to healthy individuals. The study found that cardiotrophin-1is not only an indicator of early cardiovascular complications but also a prognostic factor for the development of atherosclerosis. A positive correlation between cardiotrophin-1 levels and the atherogenic index was also established in all patient groups.

Keywords:

cardiotrophin-1 arterial hypertension type 2 diabetes mellitus obesity atherosclerosis comorbid conditions biomarkers

References:

1. Dunaieva IP. Kardiotrofin-1 yak prohnostychnyy biomarker arterialnoyi hipertenziyi ta klyuchovyy rehulyator sertsevoho metabolizmu hlyukozy. International Endocrinology Journal. 2023;19(2). doi: 10.22141/2224-0721.19.2.2023. [in Ukrainian].
2. Kobryanska OYa, Didushko OM. Suchasni mozhlyvosti vplyvu na osnovni sertsevo-sudynni faktory ryzyku u khvorykh na tsukrovyy diabet 2 typu. Mizhnarodnyi Endokrynolohichnyi Zhurnal. 2022;18(8):426-431. doi: 10.22141/2224-0721.18.8.2022.1220. [in Ukrainian].
3. Díez J, González A, López B. Cardiotrophin-1 in hypertensive heart disease: from bench to bedside. Hypertension Research. 2021;44(1):1-10. doi: 10.1038/s41440-020-0481-1.
4. Dwivedi AK, Dubey P, Cistola DP, Reddy SY. Association Between Obesity and Cardiovascular Outcomes: Updated Evidence from Meta-analysis Studies. Curr Cardiol Rep. 2020 Mar 12;22(4):25. doi: 10.1007/s11886-020-1273-y.
5. García R, Díez J, López B. Cardiotrophin-1: a key regulator of the immune system in cardiovascular diseases. Journal of Molecular and Cellular Cardiology. 2019;132:188-197. doi: 10.1016/j.yjmcc.2019.05.010.
6. González A, López B, Ravassa S, Beaumont J, Díez J. Cardiotrophin-1 as a biomarker in heart failure: a meta-analysis. Heart Failure Reviews. 2021;26(2):287-295. doi:10.1007/s10741-020-09980-9.
7. Li J, Guo Y, Zhao Z, Wang Q, Liu J, Yang Y, et al. Elevated cardiotrophin-1 levels are associated with increased risk of major adverse cardiovascular events in patients with coronary artery disease. Journal of the American Heart Association. 2020;9(3):e014927. doi: 10.1161/JAHA.119.014927.
8. López-Andrés N, Rossignol P, Vidal-Petiot E, Rossignol E, Fernández-Velasco M. Cardiotrophin-1 is involved in cardiac, vascular, and renal fibrosis in hypertension. Hypertension. 2018;72(4):942-950. doi: 10.1161/HYPERTENSIONAHA.118.11129.
9. Martínez-Martínez E, Ballesteros S, Iborra C, Blanco P, López-Andrés N, Fernández-Velasco M. Cardiotrophin-1 induces cardiac fibrosis and hypertrophy through a paracrine mechanism in hypertension. Journal of Hypertension. 2018;36(4):1000-1008. doi:10.1097/HJH.0000000000001631.
10. Sánchez-Más J, Pérez A, Moya A, Such-Miquel L, Montoro-Mateos D. Cardiotrophin-1: a new biomarker for the clinical management of heart failure. Journal of Clinical Medicine. 2020;9(3):826. doi:10.3390/jcm9030826.
11. Shaposhnyk OA, Prykhodko NP, Savchenko LV, Shevchenko TI, Sorokina SI, Yakymyshyna LI, et al. Clinical and diagnostic aspects of managing patients with valvular heart disease. Svit Medytsyny ta Biolohiyi. 2022;No 2(80):178-183. doi:10.26724/2079-8334-2022-2-80-178-183.
12. Sharif S, Saleem A, Naz S, Rashid F, Iqtedar M, Kaleem A, et al. Increased Expression of Cardiotrophin-1 in Cardiomyopathy Patients. Balkan J Med Genet. 2021 Jul 27;24(1):21-26. doi: 10.2478/bjmg-2021-0008.
13. Stejskal D, Ruzicka V. Cardiotrophin-1: review. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2018;162(1):9-19. doi:10.5507/bp.2008.011.
14. Tanaka A, Imanishi T, Kitabata H. The role of inflammation in coronary artery disease. Journal of Cardiology. 2020;71(5):359-366. doi: 10.1016/j.jjcc.2020.02.005.
15. Watanabe, T., Konii, H., Sato, K. Emerging Roles of Cardiotrophin-1 in the Pathogenesis and Biomarker of Atherosclerosis. J, 2018; 1(1), 94-105. https://doi.org/10.3390/j1010010.

Publication:

«World of Medicine and Biology» Vol. 21 No. 91 (2025) , с. 21-25
УДК 616.379-008.64+616.12-008.331.1]-056.257-078:616.13-004.6

DOI:

https://doi.org/10.26724/2079-8334-2025-1-91-21-25